Compare L & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | L | PODD |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | L | PODD |
|---|---|---|
| Price | $102.75 | $304.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $359.00 |
| AVG Volume (30 Days) | ★ 817.3K | 765.6K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.86 | 3.45 |
| Revenue | ★ $18,266,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | N/A | $32.55 |
| Revenue Next Year | N/A | $20.39 |
| P/E Ratio | ★ $15.00 | $88.24 |
| Revenue Growth | 6.06 | ★ 27.11 |
| 52 Week Low | $78.98 | $230.05 |
| 52 Week High | $109.06 | $354.88 |
| Indicator | L | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 42.64 | 40.94 |
| Support Level | $103.69 | $303.20 |
| Resistance Level | $109.06 | $317.34 |
| Average True Range (ATR) | 1.55 | 13.12 |
| MACD | -0.47 | -2.82 |
| Stochastic Oscillator | 2.02 | 3.14 |
Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.